Free tool
FAERS Monitor: Juluca
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210192 or its brand name (Juluca, Dolutegravir Sodium, Rilpivirine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,764
Serious
926
52% of reports
Hospitalization
318
Death reported
98
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain312
- product dose omission issue296
- anxiety285
- emotional distress278
- anhedonia251
- chronic kidney disease204
- renal failure132
- fatigue125
- depression120
- osteoporosis92
- acute kidney injury88
- economic problem84
- bone density decreased83
- end stage renal disease83
- renal impairment77
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 153 |
| 2019 | 263 |
| 2020 | 218 |
| 2021 | 171 |
| 2022 | 240 |
| 2023 | 247 |
| 2024 | 218 |
| 2025 | 189 |
| 2026 | 60 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,395 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anhedoniaSignal | 251 | 115.0 | 102.5 | 28,008 |
| economic problemSignal | 84 | 66.4 | 53.9 | 5,323 |
| end stage renal diseaseSignal | 83 | 54.5 | 44.2 | 4,290 |
| chronic kidney diseaseSignal | 204 | 32.1 | 28.2 | 6,121 |
| bone density decreasedSignal | 83 | 31.7 | 25.7 | 2,431 |
| emotional distressSignal | 278 | 27.4 | 24.6 | 7,081 |
| osteoporosisSignal | 92 | 26.7 | 21.9 | 2,252 |
| product dose omission issueSignal | 296 | 12.0 | 10.8 | 3,017 |
| anxietySignal | 285 | 12.0 | 10.7 | 2,885 |
| renal failureSignal | 132 | 11.9 | 10.1 | 1,309 |
| renal impairmentSignal | 77 | 10.9 | 8.8 | 687 |
| acute kidney injurySignal | 88 | 6.9 | 5.6 | 438 |
| depressionSignal | 120 | 6.3 | 5.3 | 534 |
| painSignal | 312 | 6.1 | 5.5 | 1,352 |
| fatigue | 125 | 1.9 | 1.6 | 56 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.